In 2005, scientists first discovered the JAK2 (Janus kinase 2) V617F mutation in patients with myeloproliferative neoplasms (MPNs). This discovery was like a bombshell that completely reshaped our understanding of these diseases. JAK2, a member of the JAK family, plays a critical role in cellular signal transduction. Under normal conditions, JAK2 regulates cell growth, differentiation, and immune responses, maintaining the body’s physiological balance. However, when JAK2 mutates, everything can spiral out of control. The JAK2-V617F mutation leads to abnormal activation of the JAK2 protein, keeping the JAK-STAT signaling pathway permanently “switched on.” This aberrant signaling is like opening Pandora’s box, unleashing disastrous consequences: uncontrolled cell proliferation, reduced apoptosis, and ultimately the development of hematologic diseases such as polycythemia vera, essential thrombocythemia, and myelofibrosis.
At the forefront of medical research, scientists are continuously exploring innovative strategies to overcome hematological disorders. Today, we present the JAK2 inhibitor screening platform developed by Kyinno Biotechnology.
- In vitro platform: By detecting p-STAT5-αLISA and IC50, researchers can more accurately and rapidly assess the inhibitory effects of candidate compounds on JAK2 mutation-related cells.
- In vivo platform: Through tail vein injection of Ba/F3 cells harboring JAK2 mutation-driven activation and labeled with Luc (luciferase) into mice, Kyinno has established a JAK2-driven myeloproliferative disease model. This platform allows direct visualization of JAK2 inhibitor efficacy through both in vitro and in vivo experiments.
I. In Vitro JAK2 Inhibitor Screening Platform
Kyinno Biotechnology has developed more than ten Ba/F3-derived cell lines with different JAK2-related mutations, significantly enhancing the precision and reliability of inhibitor screening.
- p-STAT5-αLISA: Used to measure inhibitor effects on downstream signaling of JAK2.
- IC50 assay: Used to evaluate cellular sensitivity to inhibitors.
II. In Vivo JAK2 Inhibitor Screening Platform
To further evaluate candidate inhibitors in preclinical settings, Ba/F3-JAK2 mutant cells were injected into mice via the tail vein, successfully establishing a myeloproliferative disease model:
- KC-3385-Ba/F3-MPL-W515L-JAK2:
- KC-3386-Ba/F3-MPL-JAK2-V617F:
- KC-1567-Ba/F3-EPOR-JAK2-V617F:
Using BALB/c nude mouse models, Ruxolitinib was shown to significantly reduce hepatosplenomegaly caused by JAK2 hyperactivation and effectively prolong the survival of diseased mice.
III. Fluorescent Models: Addressing “Pain Points” in Hematologic Malignancy Research
In hematologic cancer studies, traditional detection methods are time-consuming, labor-intensive, and poorly suited for real-time monitoring of therapeutic efficacy. By introducing fluorescently labeled cells and applying live-animal imaging technology, this problem is elegantly solved. Kyinno Biotechnology has successfully developed live mouse models for these diseases. These models not only retain the tumor cell characteristics driven by JAK2 mutations but also enable real-time monitoring of tumor cell proliferation and distribution through Luc labeling. This advancement significantly boosts research efficiency and data accuracy.
- KC-4576-Ba/F3-MPL-JAK2-V617F-EGFP-Luc2:
- KC-4678-Ba/F3-EPOR-JAK2-V617F-EGFP-Luc2:
- KC-4703-Ba/F3-EPOR-JAK2-V617F-mJAK2-KO-Luc2:
These studies demonstrate that Kyinno Biotechnology has not only built a highly efficient and reliable JAK2 inhibitor screening platform but also laid a solid foundation for the development of next-generation drugs with greater specificity and fewer side effects.
